Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2019 08:00 ET | Source: Cytta Corp.

Cytta Corp's EvrCare™ achieves Realtime Live Patient Remote Monitoring from South Pole

Las Vegas, NV, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Las Vegas, Nevada, October 17th, 2019 – Cytta Corp (OTCPINK:CYCA) Cytta is pleased to announce the successful live realtime patient trials of its...
September 03, 2019 00:01 ET | Source: FORM

FORM and Polar to Bring Heart Rate to Augmented Reality Swim Goggles

Vancouver, BC, Sept. 02, 2019 (GLOBE NEWSWIRE) -- Today, FORM, the sports technology company behind the world’s first augmented reality swim goggles, and Polar, the leader in wearable sports and...
July 15, 2019 06:00 ET | Source: Texas State Railroad

Tickets are on Sale NOW for Texas’ Authentic THE POLAR EXPRESS™ 2019 Train Ride at Texas State Railroad

PALESTINE, Texas, July 15, 2019 (GLOBE NEWSWIRE) -- Tickets are on sale now for the 2019 season of THE POLAR EXPRESS™ at Texas State Railroad. The first POLAR EXPRESS™ of the season heads to the...
January 17, 2019 02:00 ET | Source: PledPharma AB

PledPharma presenterar läkemedelskandidaten PledOx® fas III-program på global cancerkonferens

Stockholm, 17 januari 2019. PledPharma AB (publ) meddelar att bolagets globala fas III-program, POLAR, för PledOx® har accepterats för poster-presentation på den globala konferensen Gastrointestinal...
January 17, 2019 02:00 ET | Source: PledPharma AB

PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium

Stockholm, January 17, 2019. PledPharma AB (publ) announces that the company’s global phase III program, POLAR, has been accepted for a poster presentation during the Gastrointestinal (GI) Cancers...
August 15, 2018 02:00 ET | Source: PledPharma AB

PledPharma förväntar sig leverans av studieläkemedel till fas III-programmet med PledOx® i september

Stockholm, 15 augusti 2018. PledPharma AB (publ) meddelar idag att studieläkemedel till det planerade fas III-programmet med läkemedelskandidaten PledOx® förväntas kunna levereras under september...
August 15, 2018 02:00 ET | Source: PledPharma AB

Delivery of study drug to the PledOx® phase III program is expected in September

Stockholm, August 15, 2018. PledPharma AB (publ) announces today that delivery of PledOx® study drug for the planned phase III program is expected during September 2018. As previously announced,...